Regeneron's Skin Cancer Treatment Fails Late-Stage Trial Goal
Shares of Regeneron Pharmaceuticals dropped nearly 12% premarket after its experimental treatment for advanced melanoma failed to meet the primary endpoint in a late-stage trial. The combination therapy, fianlimab and cemiplimab (Libtayo), did not achieve statistical significance in improving progression-free survival compared to Merck's Keytruda.
Topics: cancer-treatment pharmaceuticals stock-market-reaction